Search

for
Search:

Research

5 / 1000+ results

research Clinical Safety and Efficacy of Dual Wavelength Low-Level Light Therapy in Androgenetic Alopecia: A Double-Blind Randomized Controlled Study

December 2024 in “Dermatologic Surgery”

This study observed that pooled analysis of LED caps increased hair density in patients with androgenetic alopecia compared to sham, achieving 28.5 more hairs per cm².

research Safety and Clinical Efficacy of KūlarisTM, an Herbal Supplement for Mild to Severe Acne Vulgaris – A 12-Week Randomized, Double Blind, Placebo-Controlled Study

September 2025 in “Clinical Cosmetic and Investigational Dermatology”

In this randomized, placebo-controlled study, Kūlaris supplementation significantly improved quality of life for participants with mild-to-severe acne over 12 weeks, though no significant changes in general skin health measures were observed compared to placebo.

research Safety and clinical considerations of alopecia therapies during pregnancy, fertility treatment, and polycystic ovary syndrome workup

June 2026 in “International Journal of Women’s Dermatology”

This review highlights significant knowledge gaps in the safety of alopecia treatments during pregnancy, IVF, and PCOS contexts, noting that many medications lack robust safety data, and underscores the need for more targeted research to guide treatment decisions.

research Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program

4 citations , November 2023 in “SKIN The Journal of Cutaneous Medicine”

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

Baricitinib is a safe and effective treatment for severe alopecia areata.

View more "clinical safety" in research →

Learn

10 / 800 results

learn SCUBE3

What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.

learn Hair Transplant

What are the risks and side effects of a hair transplant? Common risks include swelling, redness, infection, scarring, and temporary hair loss.

learn Clascoterone

Can I use clascoterone if I'm undergoing gender-affirming hormone therapy? No published clinical trial has tested clascoterone in people on gender-affirming hormone therapy, so its safety in that group is unknown. The FDA label reports low systemic exposure and no described effect on blood testosterone, but it also records HPA-axis suppression and raised potassium in a small minority of subjects.

learn Fluridil

Is Fluridil only for men with androgenetic alopecia, or can women use it too? The only published clinical study of fluridil enrolled 43 men, so its use in women is untested rather than established; women considering it should talk to a doctor, and it is not advised in pregnancy or breastfeeding because no reproductive-safety data exists.

learn Stem Cell Factor

Can stem cell factor be combined with other topical hair loss solutions? No published human trial has tested topical stem cell factor alongside minoxidil or other established treatments, so neither the safety nor the benefit of the combination has been established. Community users report layering these products, but that is anecdote rather than clinical evidence.

learn GT20029

research compound made to degrade androgen receptors in scalp

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

learn Low Level Laser Therapy

laser therapy for anti-inflammatory and likely insignificant hair regrowth effects

learn Pyrilutamide

highly targeted anti-androgen that might have minimal systemic effects

learn RU58841

a potent but unapproved and potentially problematic topical anti-androgen

View more "clinical safety" in learn →

Community Join

5 / 1000+ results

community Hair Regrowth Following a Wnt- and Follistatin- Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial: Scientific, Peer-Reviewed Dermatology Article Indexed with MEDLINE/PubMed

4 upvotes 12 years ago

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

community Pp405 phase 2a clinical results

37 upvotes 1 year ago

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results

in Update 415 upvotes 1 year ago

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

community If PP405 goes systemic this would be quite catastrophic

in Research/Science 4 upvotes 1 year ago

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

community New article on PP405..........

in Research/Science 109 upvotes 1 year ago

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

View more "clinical safety" in community →

Clinics

6 / 500 results

All 500 clinic results →

Experts

— no results

Try a deeper search in experts →